Disease-Elevated CHI3L1/CHIT1 Chitinases Are Biomarkers and Partial Compensators for Senescent Microglial Phagocytic Failure
🧪 Overview
CHI3L1 (YKL-40), CHIT1 (chitotriosidase), and CHI3L2 are among the most consistently elevated proteins in ALS biofluids and tissue, making them strong candidate disease biomarkers. In sporadic ALS CSF, CHIT1 shows strong elevation and was among the first candidate biomarkers identified for the disease (PMID:24295388). Consistent with this, CSF CHIT1, CHI3L1, and CHI3L2 correlate with neuroinflammatory disease state across patient cohorts (PMID:31123140). At the tissue level, CHI3L1 and CHI3L2 are overexpressed in motor cortex and spinal cord from sporadic ALS patients, indicating disease-linked glial activation in affected CNS regions (PMID:28989002). Chitotriosidase activity specifically functions as a biomarker of microglial activation in ALS, reflecting the prominent innate immune component of the disease (PMID:30134252).\n\nThe hypothesis proposes that these chitinases are not merely markers but function as partial compensators for senescent microglial phagocytic failure.
...🧬 Mechanism
Curated pathway from expert analysis
flowchart TD
A["Microglial Priming<br/>Pre-Symptomatic Activation"]
B["CHI3L1/YKL-40 Secretion<br/>Chitinase-3-Like Protein 1"]
C["CSF Biomarker<br/>Elevated Before Tau/Abeta"]
D["Extracellular Matrix<br/>Remodeling"]
E["Tissue Fibrosis<br/>Gliosis Response"]
F["Astrocyte Activation<br/>A1 Reactive Phenotype"]
G["Synaptic Environment<br/>Degradation"]
H["Neurodegeneration<br/>AD Progression"]
A --> B
B --> C
B --> D
D --> E
B --> F
E --> G
F --> G
G --> H
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style C fill:#7b1fa2,stroke:#ce93d8,color:#ce93d8
style H fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a⚖️ Evidence
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — CHI3L1
No curated PDB or AlphaFold mapping for CHI3L1 yet. Search RCSB →
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for CHI3L1 (YKL-40), CHIT1, CHI3L2 / MMP-2 / TREM2 / MerTK from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for CHI3L1 (YKL-40), CHIT1, CHI3L2.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
📊 Market Indicators
💾 Resource Usage
🔮 Predictions
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF ALS patients with CSF CHIT1 levels in the highest tertile (>75th percentile) are compared to those in the lowest tertile (<25th percentile) at baseline, THEN the high-CHIT1 cohort will demonstrate | Slower functional decline and longer survival in high-CSIT1 ALS patients | — no observation — | pending | 0.55 |
| IF CHIT1 catalytic activity is pharmacologically inhibited (e.g., via Csnama-derivative compound) in SOD1G93A transgenic mice at disease onset, THEN neurofilament light chain (NF-L) levels in plasma w | Accelerated neurodegeneration biomarker elevation and motor function decline in CHIT1-inhibited group | — no observation — | pending | 0.45 |
▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
| source | v1_phase_c_backfill |
| origin_type | gap_debate |
| _schema_version | 1 |